Paradigm Biopharmaceuticals Ltd has released a press release.
Aus ethics approval received for phase 3 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- 2021 Annual Report and Appendix 4E
- Paradigm reports ind application update
- Paradigm submits responses to US FDA questions
- Paradigm receives key regulatory approvals for mps vi study
- Ind questions received from US FDA
Later from Paradigm Biopharmaceuticals
- Paradigm receives feedback from US FDA on ind submission
- First mps-vi patient dosed under phase 2 trial in Brazil
- Positive top-line results from preclinical study in ards
- Phase 2 Synovial Fluid Biomarker Study Update
- Paradigm cleared for phase 3 trial by US FDA
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals